Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127550921 | 12755092 | 1 | I | 20160909 | 20160916 | 20160916 | EXP | PHHY2016VE126550 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160916 | CN | COUNTRY NOT SPECIFIED | VE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127550921 | 12755092 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 800 MG, QD | 22068 | 800 | MG | CAPSULE | QD | ||||||
| 127550921 | 12755092 | 2 | SS | TASIGNA | NILOTINIB | 1 | Oral | 400 MG, QD | 22068 | 400 | MG | CAPSULE | QD | ||||||
| 127550921 | 12755092 | 3 | SS | TASIGNA | NILOTINIB | 1 | Oral | 800 MG, QD | 22068 | 800 | MG | CAPSULE | QD |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127550921 | 12755092 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127550921 | 12755092 | Asthenia | |
| 127550921 | 12755092 | Depressed mood | |
| 127550921 | 12755092 | Drug intolerance | |
| 127550921 | 12755092 | Headache | |
| 127550921 | 12755092 | Memory impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127550921 | 12755092 | 1 | 20131212 | 0 |